Skip to main content
Premium Trial:

Request an Annual Quote

People in the News: Tina Nova, Rick Klausner, Paul Menter

Premium

Illumina has named Tina Nova as the senior vice president and general manager of its oncology business. Nova replaces Rick Klausner, who has served as interim oncology leader since January. Klauner will continue to serve as senior vice president and chief medical officer, Illumina said.

Nova is the co-founder of Genoptix and previously served as the firm's president and CEO. She also co-founded Nanogen, where she was COO and president. Nova holds a BSc in biological sciences from the University of California, Irvine and a PhD in biochemistry from the University of California, Riverside.


Paul Menter has joined SomaLogic as vice president and general manager of its life science tools business.

Menter most recently served as general manager of Bioseparations at Thermo Fisher Scientific. Before that, he was division manager of lab separations and of North American sales and service at Bio-Rad Laboratories.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.